Accessibility Menu
Thc Therapeutics logo

Thc Therapeutics(OTC) THCT

Market Cap$24.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-99%
1 Year+500%
1 Month+20%
$0.00
+0.00%
+0.00Today
Thc Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-10
Thc Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-31
1 month+20%USD 0.002026-07-09
3 month-45.45%USD 0.002026-05-11
Year to date+500%USD 0.002025-12-31
1 year+500%USD 0.002025-08-07
3 year-80%USD 0.002023-08-11
5 year-99.48%USD 0.122021-08-11
Since inception-99.97%USD 2.052017-01-24

Thc Therapeutics Financials at a Glance

Market Cap

$24.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$562.78K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

21.73 (High)

Price

$0.00

Volume

10

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

Nov 11, 2025

THCT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Thc Therapeutics

THC Therapeutics makes devices to dry and sanitize herbs, mainly cannabis. Its main product, the dHydronator, helps growers reduce drying time and improve safety. The company targets cannabis producers and wellness businesses needing faster, cleaner processing.

Products and Services

  • dHydronator herb dryer: Patented device using ultraviolet light to dry and sanitize cannabis and herbs. (0% of revenue in 2024, as no sales reported)
  • Genesis Float Spa assets: Previously marketed floatation therapy equipment for wellness centers. (0% of revenue in 2024)
  • Intellectual property licensing: Patents and trademarks related to herb drying technology. (0% of revenue in 2024)

Growth and Expansion

  • Changed name from Millennium Blockchain to THC Therapeutics in 2018 to focus on wellness and cannabis technology.
  • Acquired The Headquarters Group, Inc. (Oregon) and subsidiaries in June 2025 via share exchange.
  • Signed agreement to acquire ST Holdings Group, LLC in July 2025 (not yet closed).
  • Plans to expand through trade shows and field tests with legal cannabis growers in the U.S. and Canada.

What Makes THC Therapeutics Stand Out

The company holds a U.S. patent for its dHydronator, which uses ultraviolet light to sanitize herbs. Independent labs have validated its ability to reduce drying time and lower bacteria in cannabis. THC Therapeutics focuses on intellectual property and aims to license or manufacture its technology for the cannabis industry.

Five Things You Need to Know

  • No revenue reported for 2022, 2023, or 2024.
  • Net loss was $811,562 in FY 2024, up 110% from FY 2023.
  • Cash on hand was $35 as of July 31, 2024.
  • Working capital deficit reached $3.7 million in July 2024.
  • Company depends on raising new capital to continue operations.

Bottom Line

THC Therapeutics remains pre-revenue, focused on developing and protecting its herb drying technology. The company faces significant financial challenges but continues to seek growth through acquisitions and industry partnerships.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

1

CEO

Scott A. Cox

Website

thct.io

Headquarters

Jacksboro, TX 76458, US

THCT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

12.06%

Return on Capital

N/A

Return on Assets

-2979.49%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.27M

Volume

10

Avg. Volume

285.873

Financials (TTM)

Gross Profit

-$1.40K

Operating Income

-$574.72K

EBITDA

-$483.83K

Operating Cash Flow

-$182.51K

Capital Expenditure

$0.00

Free Cash Flow

-$182.51K

Cash & ST Invst.

$849.00

Total Debt

$731.79K

Thc Therapeutics Performance Analysis

Thc Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31USD 0N/A
20232023-07-31USD 0N/A
20242024-07-31USD 0N/A
Thc Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-07-31N/A
Q12023-10-31N/A
Q22024-01-31N/A
Q32024-04-30N/A
Thc Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31USD -0.05N/A
20232023-07-31USD -0.01-74.2%
20242024-07-31USD -0.0293.2%
Thc Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-07-31-134.5%
Q12023-10-31-90.0%
Q22024-01-31-815.8%
Q32024-04-30115.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$344.00

-1.2%

Gross Margin

0.00%

N/A

Market Cap

$24.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$24.20K

N/A

Employees

1

N/A

Net Income

$104.62K

+10.9%

EBITDA

$123.30K

+8.2%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$849.00

+5560.0%

Total Debt

$731.79K

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$731.79K

+0.0%

Return on Assets

-29.79%

N/A

Return on Invested Capital

15.39%

N/A

Free Cash Flow

-$137.06K

-6192.9%

Operating Cash Flow

-$137.06K

-6193.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NMXSNet Medical Xpress Solutions, Inc.
$0.00+0.00%
QMDTQuick-Med Technologies, Inc.
$0.00+0.00%
REMIRemedent, Inc.
$0.00+0.00%
EMGEEmergent Health Corp
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About THCT

What is the current price of Thc Therapeutics?

Thc Therapeutics is trading at $0.00 per share.

What is the 52-week range for Thc Therapeutics?

Over the past 52 weeks, Thc Therapeutics has traded between $0.00 and $0.10.

How much debt does Thc Therapeutics have?

As of the most recent reporting period, Thc Therapeutics reported total debt of $876.90K.

How much cash does Thc Therapeutics have on hand?

Thc Therapeutics reported $35.00 in cash and cash equivalents in its most recent financial results.

What is Thc Therapeutics’s dividend yield?

Thc Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services